We used H22 hepatoma tumor-bearing mice and a Sor-resistant human hepatoma cell line to investigate the antihepatoma effect of PFGS combined with Sor in vivo and in vitro, as well as the corresponding mechanism centered on the upstream and downstream target genes of the NF-κB signaling pathway, laying the foundation for the clinical application of Shaoyao Ruangan Mixture and Sor. Here, NFKB1 is linked to hepatocellular carcinoma.